Ann: Change of principal place of business, page-22

There is a business, there are sales, and the Osprey registry is showing clinical results.

CE mark is necessary but trials convince doctors to use it and governments to reimburse it.

Remember we had 2 years of Covid immediately post CE mark so no one from the company could even physically go into a hospital. We are 1 year into a new period.

Trials, with experience and publications from the trials, are the basis for adoption and growth. And the company is funding, and has commenced, at least 2 really good trials right now. They are both required for reimbursement and the only form of marketing that makes any difference in medicine. Have a look around at some big names on ASX right now that still don't engage in RCTs for fear of failing them.

The thing that I see that is very exciting is that the surgical resection rate continues to hold at the rate seen in PANCO study.

As I've mentioned before, new centres starting to use the technology is a good proxy for future sales growth, and we have seen the number of new centres starting to use Oncosil slowly climbing. A shift for use in palliation would make a huge difference too eventually.

I guess the thing that annoys me is seeing so many other companies on ASX with much less potential that have huge market caps on the basis of retail shareholder excitement. We don;t seem to ignite those animal spirits